Muscular Atrophy, Spinal
A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)
Subtype terms (2)
More specific conditions that are subtypes of Muscular Atrophy, Spinal in the MeSH hierarchy.
- Bulbo-Spinal Atrophy, X-Linked
8 drugs (4 approved, 4 experimental)
- Spinal Muscular Atrophies of Childhood
14 drugs (9 approved, 5 experimental)
Drugs by status
Approved for this indication (4)
Phase 3 trials (8)
Phase 2 trials (13)
Phase 1 trials (4)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (32)
- Abbott
- Roche
- Astellas
- Novo Nordisk
- Novartis
- Catalyst Pharmaceuticals, Inc.
- Leadiant Biosciences, Inc.
- Westat
- Cytokinetics
- Stem Cells Arabia
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Bambino Gesù Hospital and Research Institute
- Duke University
- Hoosier Cancer Research Network
- Johns Hopkins University
- Ohio State University
- Stanford University
- University of Ottawa
- University of Tehran
- Utrecht University
- University of Utah
- University of Freiburg
- Isfahan University
- Families of Spinal Muscular Atrophy
- CHR Citadelle
- Carlo Besta Neurological Institute
- Families of SMA Canada
- Gwendolyn Strong
- +2 more
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (5)